Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate CAY001 in Healthy Volunteers

NCT06845839
Conditions
Healthy
Interventions
CAY001, Placebo
Drug · Other
Lead sponsor
Cayuga Biotech, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Conditions
Pulmonary Embolism
Interventions
Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging
Drug
Lead sponsor
Cyclomedica Australia PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Central Retinal Vein Occlusion

NCT01468844
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Results available

ODEN Trial: Option vs. Denali IVC Filters

NCT02201277
Conditions
Venous Thromboembolism
Interventions
Filter Placed
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Number of Deep Venous Thrombosis (DVT)
Interventions
Doppler Ultrasound
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Conditions
Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism
Interventions
Celect Platinum Vena Cava Filter
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Conditions
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
76
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
Conditions
Pulmonary Embolism
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population

NCT00356434
Conditions
Thrombophilia
Interventions
Kendall A-V foot impulse pump, model 6060, Kendall sequential compression device, model 9525
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Withdrawn Phase 3 Interventional

Macitentan to Prevent PRVO

NCT05946811
Conditions
Pulmonary Embolism
Interventions
Macitentan 10mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Not listed No phase listed Observational

APPEND-CT Registry

NCT06213285
Conditions
Stroke, Ischemic, Device Related Thrombosis, Atrial Fibrillation
Interventions
Watchman FLX left atrial appendage occlusion
Device
Lead sponsor
Aarhus University Hospital
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Diseases, Pulmonary Embolism
Interventions
Magnetic Resonance Angiography, Magnetic Resonance Venography
Procedure
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Atlanta, Georgia • Bethesda, Maryland • Rockville, Maryland + 5 more
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Glioblastoma, Astrocytoma, Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Venous Thromboembolism
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Conditions
Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions
IV normal saline, IV immunoglobulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Identifying the Anti-Blood-Clotting Compounds in Garlic

NCT00200785
Conditions
Arteriosclerosis, Intracranial Arteriosclerosis
Interventions
garlic powder added to ambient water, garlic powder added to boiling water
Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orem, Utah